Prevention and Treatment of Stricturing Crohn’s Disease – Perspectives and Challenges

References

• Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory Bowel diseases. Gastroenterology. 2017;152(2):340–350 e6.
   PubMed Web of Science ®Google Scholar
• Rieder F. Managing intestinal fibrosis in patients with inflammatory Bowel disease. Gastroenterol Hepatol. 2018;14(2):120–122.
   Google Scholar
• Yoo JH, Holubar S, Rieder F. Fibrostenotic strictures in Crohn’s disease. Intest Res. 2020;18(4):379–401.
   PubMed Web of Science ®Google Scholar
• Golovics PA, Lakatos L, Mandel MD, et al. Prevalence and predictors of hospitalization in Crohn’s disease in a prospective population-based inception cohort from 2000–2012. World J Gastroenterol. 2015;21(23):7272.
   PubMed Web of Science ®Google Scholar
• Bettenworth D, Rieder F. Reversibility of stricturing Crohn’s disease-fact or fiction? Inflamm Bowel Dis. 2016;22(1):241–247.
   PubMed Web of Science ®Google Scholar
• Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777–782.
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–1155.
   PubMed Web of Science ®Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68(3):423–433.
   PubMed Web of Science ®Google Scholar
• El Ouali S, Click B, Holubar SD, et al. Natural history, diagnosis and treatment approach to fibrostenosing Crohn’s disease. United European Gastroenterol J. 2020;8(3):263–270.
   PubMed Web of Science ®Google Scholar
• Jurgens M, Brand S, Laubender RP, et al. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn’s disease independent of the IL23R genotype. J Gastroenterol. 2010;45(7):721–731.
   PubMed Web of Science ®Google Scholar
• Oberhuber G, Stangl PC, Vogelsang H, et al. Significant association of strictures and internal fistula formation in Crohn’s disease. Virchows Arch. 2000;437(3):293–297.
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699–706.
   PubMed Web of Science ®Google Scholar
• Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn’s disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985;88(6):1818–1825.
   PubMed Web of Science ®Google Scholar
• Fumery M, Pineton de Chambrun G, Stefanescu C, et al. Detection of dysplasia or cancer in 3.5% of patients with inflammatory Bowel disease and Colonic strictures. Clin Gastroenterol Hepatol. 2015;13(10):1770–1775.
   PubMed Web of Science ®Google Scholar
• Lovasz BD, Lakatos L, Golovics PA, et al. Risk of colorectal cancer in Crohn’s disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary. J Gastrointestin Liver Dis. 2013;22(3):265–268.
   PubMed Web of Science ®Google Scholar
• Lu C, Holubar SD, Rieder F. How I approach the management of stricturing Crohn’s disease. Am J Gastroenterol. 2019;114(8):1181–1184.
   PubMed Web of Science ®Google Scholar
• Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL Cohort. Am J Gastroenterol. 2017;112(2):325–336.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710–1718.
   PubMed Web of Science ®Google Scholar
• Lazarev M, Ullman T, Schraut WH, et al. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010;16(5):830–835.
   PubMed Web of Science ®Google Scholar
• Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62(7):1072–1084.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–963.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Lipton DS, Fiest KM, et al. Cumulative incidence of second intestinal resection in Crohn’s disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109(11):1739–1748.
   PubMed Web of Science ®Google Scholar
• Zhao JF, Ling FM, Li JR, et al. Role of non-inflammatory factors in intestinal fibrosis. J Dig Dis. 2020;21(6):315–318.
   PubMed Web of Science ®Google Scholar
• Sadler T, Bhasin JM, Xu Y, et al. Genome-wide analysis of DNA methylation and gene expression defines molecular characteristics of Crohn’s disease-associated fibrosis. Clin Epigenetics. 2016;8:30.
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178(9):948–955.
   PubMed Web of Science ®Google Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157(6):398–406.
   PubMed Web of Science ®Google Scholar
• Chen W, Lu C, Hirota C, et al. Smooth muscle hyperplasia/hypertrophy is the most prominent histological change in Crohn’s fibrostenosing Bowel strictures: a semiquantitative analysis by using a novel histological grading scheme. J Crohns Colitis. 2017;11(1):92–104.
   PubMed Web of Science ®Google Scholar
• Zidar N, Langner C, Jerala M, et al. Pathology of fibrosis in Crohn’s disease-contribution to understanding its pathogenesis. Front Med (Lausanne). 2020;7:167.
   PubMed Web of Science ®Google Scholar
• Lim WW, Ng B, Widjaja A, et al. Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice. PLoS One. 2020;15(1):e0227505.
   PubMed Web of Science ®Google Scholar
• Latella G, Viscido A. Controversial contribution of Th17/IL-17 toward the immune response in intestinal fibrosis. Dig Dis Sci. 2020;65(5):1299–1306.
   PubMed Web of Science ®Google Scholar
• Franze E, Dinallo V, Laudisi F, et al. Interleukin-34 stimulates gut fibroblasts to produce collagen synthesis. J Crohns Colitis. 2020;9
   Google Scholar
• Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol. 2007;179(10):6988–7000.
   PubMed Web of Science ®Google Scholar
• Rieder F, Kessler S, Sans M, et al. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G786–801.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Rodansky ES, Sauder KL, et al. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts. Inflamm Bowel Dis. 2013;19(5):891–903.
   PubMed Web of Science ®Google Scholar
• Ura H, Obara T, Yokota K, et al. Effects of transforming growth factor-beta released from gastric carcinoma cells on the contraction of collagen-matrix gels containing fibroblasts. Cancer Res. 1991;51(13):3550–3554.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Rodansky ES, Haak AJ, et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014;20(1):154–165.
   PubMed Web of Science ®Google Scholar
• Zhao S, Dejanovic D, Yao P, et al. Selective deletion of MyD88 signaling in alpha-SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation. Mucosal Immunol. 2020;13(4):665–678.
   PubMed Web of Science ®Google Scholar
• Rieder F, Bettenworth D, Ma C, et al. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment Pharmacol Ther. 2018;48(3):347–357.
   PubMed Web of Science ®Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–989.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512.
   PubMed Web of Science ®Google Scholar
• Khanna R, Zou G, Stitt L, et al. Responsiveness of endoscopic indices of disease activity for Crohn’s disease. Am J Gastroenterol. 2017;112(10):1584–1592.
   PubMed Web of Science ®Google Scholar
• Bettenworth D, Bokemeyer A, Baker M, et al. Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut. 2019;68(6):1115–1126.
   PubMed Web of Science ®Google Scholar
• Maconi G, Carsana L, Fociani P, et al. Small bowel stenosis in Crohn’s disease: clinical, biochemical and ultrasonographic evaluation of histological features. Aliment Pharmacol Ther. 2003;18(7):749–756.
   PubMed Web of Science ®Google Scholar
• Vogel J, da Luz Moreira A, Baker M, et al. CT enterography for Crohn’s disease: accurate preoperative diagnostic imaging. Dis Colon Rectum. 2007;50(11):1761–1769.
   PubMed Web of Science ®Google Scholar
• Pous-Serrano S, Frasson M, Palasi Gimenez R, et al. Accuracy of magnetic resonance enterography in the preoperative assessment of patients with Crohn’s disease of the small bowel. Colorectal Dis. 2017;19(5):O126–O133.
   PubMed Web of Science ®Google Scholar
• Kumar S, Hakim A, Alexakis C, et al. Small intestinal contrast ultrasonography for the detection of small bowel complications in Crohn’s disease: correlation with intraoperative findings and magnetic resonance enterography. J Gastroenterol Hepatol. 2015;30(1):86–91.
   PubMed Web of Science ®Google Scholar
• Rieder F, Latella G, Magro F, et al. European Crohn’s and colitis organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn’s disease. J Crohns Colitis. 2016;10(8):873–885.
   PubMed Web of Science ®Google Scholar
• Rimola J, Capozzi N. Differentiation of fibrotic and inflammatory component of Crohn’s disease-associated strictures. Intest Res. 2020;18(2):144–150.
   PubMed Web of Science ®Google Scholar
• Shivaji UN, Evans M, Critchlow T, et al. Chronic inflammation and other changes are significant components of clinically fibrotic strictures in Crohn’s disease: a histological study of resected strictures clinically characterized as noninflamed. Eur J Gastroenterol Hepatol. 2020;32(11):1432–1439.
   PubMed Web of Science ®Google Scholar
• Adler J, Punglia DR, Dillman JR, et al. Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn’s disease. Inflamm Bowel Dis. 2012;18(5):849–856.
   PubMed Web of Science ®Google Scholar
• Chiorean MV, Sandrasegaran K, Saxena R, et al. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol. 2007;102(11):2541–2550.
   PubMed Web of Science ®Google Scholar
• Rimola J, Planell N, Rodriguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110(3):432–440.
   PubMedGoogle Scholar
• Gordon IO, Bettenworth D, Bokemeyer A, et al. Histopathology scoring systems of stenosis associated with small Bowel Crohn’s disease: a systematic review. Gastroenterology. 2020;158(1):137–150.e1.
   PubMed Web of Science ®Google Scholar
• Keuchel M, Kurniawan N, Baltes P. Small bowel ulcers: when is it not inflammatory bowel disease ? Curr Opin Gastroenterol. 2019;35(3):213–222.
   PubMed Web of Science ®Google Scholar
• Yaffe BH, Korelitz BI. Prognosis for nonoperative management of small-bowel obstruction in Crohn’s disease. J Clin Gastroenterol. 1983;5(3):211–215.
   PubMed Web of Science ®Google Scholar
• Lowe SC, Ream J, Hudesman D, et al. A clinical and radiographic model to predict surgery for acute small bowel obstruction in Crohn’s disease. Abdom Radiol. 2020;45(9):2663–2668 .
   PubMed Web of Science ®Google Scholar
• de Souza GS, Vidigal FM, Chebli LA, et al. Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn’s disease patients. Med Sci Monit. 2013;19:716–722.
   PubMed Web of Science ®Google Scholar
• Vidigal FM, de Souza GS, Chebli LA, et al. Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn’s disease. Med Sci Monit. 2014;20:2165–2170.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342(22):1627–1632.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–297. .
   PubMed Web of Science ®Google Scholar
• Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67(1):53–60.
   PubMed Web of Science ®Google Scholar
• Pallotta N, Barberani F, Hassan NA, et al. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14(12):1885–1890.
   PubMed Web of Science ®Google Scholar
• Allocca M, Bonifacio C, Fiorino G, et al. Efficacy of tumour necrosis factor antagonists in stricturing Crohn’s disease: a tertiary center real-life experience. Dig Liver Dis. 2017;49(8):872–877.
   PubMedGoogle Scholar
• Pelletier AL, Kalisazan B, Wienckiewicz J, et al. Infliximab treatment for symptomatic Crohn’s disease strictures. Aliment Pharmacol Ther. 2009;29(3):279–285.
   PubMed Web of Science ®Google Scholar
• Holtmann M, Wanitschke R, Helisch A, et al. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn’s disease]. Z Gastroenterol. 2003;41(1):11–17.
   PubMed Web of Science ®Google Scholar
• Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn’s disease. Aliment Pharmacol Ther. 2020;51(12):1233–1246. .
   PubMed Web of Science ®Google Scholar
• Toy LS, Scherl EJ, Kornbluth A, et al. Complete bowel obstruction following initial response to infliximab therapy for crohn’s disease: a series of a newly described complication. Gastroenterology. 2000;118(4):A569.
   Web of Science ®Google Scholar
• Vasilopoulos S, Kugathasan S, Saeian K, et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn’s disease. Am J Gastroenterol. 2000;95(9):2503.
   Google Scholar
• Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101(5):1030–1038.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lago I, Hoyo JD, Perez-Girbes A, et al. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease. United European Gastroenterol J. 2020;8(9):1056–1066.
   Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627 e3.
   PubMed Web of Science ®Google Scholar
• Elmoursi A, Barrett TA, Perry C. Double biologic therapy for refractory stricturing Crohn’s disease: a successful case of deep remission with ustekinumab and vedolizumab. Inflamm Bowel Dis. 2020;26(7):e62–e63.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–1155.
   PubMed Web of Science ®Google Scholar
• Bettenworth D, Gustavsson A, Atreja A, et al. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn’s disease. Inflamm Bowel Dis. 2017;23(1):133–142.
   PubMed Web of Science ®Google Scholar
• Bettenworth D, Mucke MM, Lopez R, et al. Efficacy of endoscopic dilation of gastroduodenal Crohn’s disease strictures: a systematic review and meta-analysis of individual patient data. Clin Gastroenterol Hepatol. 2019;17(12):2514–2522 e8.
   PubMed Web of Science ®Google Scholar
• Bettenworth D, Rieder F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair. 2014;7(1):5.
   PubMedGoogle Scholar
• Navaneethan U, Lourdusamy V, Njei B, et al. Endoscopic balloon dilation in the management of strictures in Crohn’s disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc. 2016;30(12):5434–5443.
   PubMed Web of Science ®Google Scholar
• Thienpont C, D’Hoore A, Vermeire S, et al. Long-term outcome of endoscopic dilatation in patients with Crohn’s disease is not affected by disease activity or medical therapy. Gut. 2010;59(3):320–324.
   PubMed Web of Science ®Google Scholar
• East JE, Brooker JC, Rutter MD, et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn’s strictures. Clin Gastroenterol Hepatol. 2007;5(9):1065–1069.
   PubMed Web of Science ®Google Scholar
• Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohn’s Colitis. 2019;14(2):155–168.
   Google Scholar
• Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn’s disease: report of nine-year follow-up and review of the literature. Inflamm Bowel Dis. 2011;18(3):506–512.
   PubMed Web of Science ®Google Scholar
• Attar A, Maunoury V, Vahedi K, et al. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn’s disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012;18(10):1849–1854.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Ricci E, Pedrazzoli C, et al. Endoscopic dilation of anastomotic colonic stenosis by different techniques: an alternative to surgery? Gastrointest Endosc. 1987;33(1):21–24.
   PubMed Web of Science ®Google Scholar
• Lan N, Shen B. Endoscopic stricturotomy with needle knife in the treatment of strictures from inflammatory Bowel disease. Inflamm Bowel Dis. 2017;23(4):502–513.
   PubMed Web of Science ®Google Scholar
• Moroi R, Shiga H, Kuroha M, et al. Endoscopic radial incision and cutting for Crohn’s disease-associated intestinal stricture: a pilot study. Endosc Int Open. 2020;8(1):E81–E86.
   PubMed Web of Science ®Google Scholar
• Strong S, Steele SR, Boutrous M, et al. Clinical practice guideline for the surgical management of Crohn’s disease. Dis Colon Rectum. 2015;58(11):1021–1036.
   PubMed Web of Science ®Google Scholar
• Aratari A, Papi C, Leandro G, et al. Early versus late surgery for ileo-caecal Crohn’s disease. Aliment Pharmacol Ther. 2007;26(10):1303–1312.
   PubMed Web of Science ®Google Scholar
• Latella G, Cocco A, Angelucci E, et al. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen. Dig Liver Dis. 2009;41(4):269–276.
   PubMedGoogle Scholar
• Golovics PA, Lakatos L, Nagy A, et al. Is early limited surgery associated with a more benign disease course in Crohn’s disease? World J Gastroenterol. 2013;19(43):7701–7710.
   PubMed Web of Science ®Google Scholar
• Patel SV, Patel SV, Ramagopalan SV, et al. Laparoscopic surgery for Crohn’s disease: a meta-analysis of perioperative complications and long term outcomes compared with open surgery. BMC Surg. 2013;13:14.
   PubMed Web of Science ®Google Scholar
• Gaglani T, Davis CH, Bailey HR, et al. Trends and outcomes for minimally invasive surgery for inflammatory Bowel disease. J Surg Res. 2019;235:303–307.
   PubMed Web of Science ®Google Scholar
• Strong SA. Strictureplasty in complex Crohn’s disease: beyond the basics. Clin Colon Rectal Surg. 2019;32(4):243–248.
   PubMed Web of Science ®Google Scholar
• Lee CHA, Rieder F, Holubar SD. Duodenojejunal bypass and strictureplasty for diffuse small Bowel Crohn’s disease with a step-by-step visual guide. Crohn’s Colitis. 2019;1(1).
   Google Scholar
• Alshantti A, Hind D, Hancock L, et al. The role of Kono-S anastomosis and mesenteric resection in reducing recurrence after surgery for Crohn’s disease: a systematic review. Colorectal Dis. 2020;n/a(n/a).
   Google Scholar
• Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50(11):1968–1986.
   PubMed Web of Science ®Google Scholar
• de Buck van Overstraeten A, Vermeire S, Vanbeckevoort D, et al. Modified side-to-side isoperistaltic strictureplasty over the ileocaecal valve: an alternative to ileocaecal resection in extensive terminal ileal Crohn’s disease. J Crohns Colitis. 2016;10(4):437–442.
   PubMed Web of Science ®Google Scholar
• Maconi G, Sampietro GM, Cristaldi M, et al. Preoperative characteristics and postoperative behavior of bowel wall on risk of recurrence after conservative surgery in Crohn’s disease: a prospective study. Ann Surg. 2001;233(3):345–352.
   PubMed Web of Science ®Google Scholar
• Fazio VW, Tjandra JJ, Lavery IC, et al. Long-term follow-up of strictureplasty in Crohn’s disease. Dis Colon Rectum. 1993;36(4):355–361.
   PubMed Web of Science ®Google Scholar
• Mohan HM, Coffey JC. Surgical treatment of intestinal stricture in inflammatory bowel disease. J Dig Dis. 2020;21(6):355–359.
   PubMed Web of Science ®Google Scholar
• Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res. 2005;65(3):694–701.
   PubMed Web of Science ®Google Scholar
• Oshitani N, Yamagami H, Watanabe K, et al. Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn’s disease. Gut. 2007;56(4):599–600.
   PubMed Web of Science ®Google Scholar
• Kadir S-I, Wenzel Kragstrup T, Dige A, et al. Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn’s disease. Scand J Gastroenterol. 2016;51(11):1321–1325.
   PubMed Web of Science ®Google Scholar
• Scheibe K, Kersten C, Schmied A, et al. Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology. 2019;156(4):1082–1097. e11.
   PubMed Web of Science ®Google Scholar
• Rieder F. ROCKing the field of intestinal fibrosis or between a rock and a hard place? Gastroenterology. 2017;153(4):895–897.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Devriese S, Castermans K, et al. Treatment of intestinal fibrosis in experimental inflammatory Bowel disease by the pleiotropic actions of a local rho kinase inhibitor. Gastroenterology. 2017;153(4):1054–1067.
   PubMed Web of Science ®Google Scholar
• Speca S, Rousseaux C, Dubuquoy C, et al. Novel PPARγ modulator GED-0507-34 levo ameliorates inflammation-driven intestinal fibrosis. Inflamm Bowel Dis. 2016;22(2):279–292.
   PubMed Web of Science ®Google Scholar
• Chen H, Xu H, Luo L, et al. Thalidomide prevented and ameliorated pathogenesis of Crohn’s disease in mice via regulation of inflammatory response and fibrosis. Front Pharmacol. 2019;10. DOI:https://doi.org/10.3389/fphar.2019.01486.
   Google Scholar
• Gao J, Cui J, Zhong H, et al. Andrographolide sulfonate ameliorates chronic colitis induced by TNBS in mice via decreasing inflammation and fibrosis. Int Immunopharmacol. 2020;83:106426.
   Web of Science ®Google Scholar
• Liu W, Guo W, Guo L, et al. Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response. Int Immunopharmacol. 2014;20(2):337–345.
   PubMed Web of Science ®Google Scholar
• Binabaj MM, Asgharzadeh F, Avan A, et al. EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation. J Cell Physiol. 2019;234(7):11654–11661.
   PubMed Web of Science ®Google Scholar
• Imai J, Yahata T, Ichikawa H, et al. Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice. Intestinal Res. 2020;18(2):219–228.
   Web of Science ®Google Scholar
• Cui Y, Zhang M, Leng C, et al. Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts. Cells. 2020;9(3):775.
   Web of Science ®Google Scholar
• Guan Q, Ma Y, Hillman CL, et al. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine. 2009;27(50):7096–7104.
   PubMed Web of Science ®Google Scholar
• Guan Q, Ma Y, Hillman CL, et al. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol Med. 2011;17(7–8):646–656.
   PubMed Web of Science ®Google Scholar
• Guan Q, Weiss CR, Wang S, et al. Reversing ongoing chronic intestinal inflammation and fibrosis by sustained block of IL-12 and IL-23 using a vaccine in mice. Inflamm Bowel Dis. 2018;24(9):1941–1952.
   PubMed Web of Science ®Google Scholar
• Wu F, Shao Q, Hu M, et al. Wu-Mei-Wan ameliorates chronic colitis-associated intestinal fibrosis through inhibiting fibroblast activation. J Ethnopharmacol. 2020;252:112580.
   Web of Science ®Google Scholar
• Lewis A, Nijhuis A, Berti G, et al. P035 Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease. J Crohn’s Colitis. 2019;13(Supplement_1):S103–S104.
   Google Scholar
• Ziogas DC, Gras-Miralles B, Mustafa S, et al. Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2013;304(10):G876–G884.
   PubMed Web of Science ®Google Scholar
• Hiraishi K, Kurahara L-H, Sumiyoshi M, et al. Daikenchuto (Da-Jian-Zhong-Tang) ameliorates intestinal fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel. World J Gastroenterol. 2018;24(35):4036–4053.
   PubMed Web of Science ®Google Scholar
• Wengrower D, Zanninelli G, Latella G, et al. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol. 2012;26(1):33–39.
   PubMed Web of Science ®Google Scholar
• Tao Q, Wang B, Zheng Y, et al. Triptolide ameliorates colonic fibrosis in an experimental rat model. Mol Med Rep. 2015;12(2):1891–1897.
   PubMed Web of Science ®Google Scholar
• Steiner CA, Rodansky ES, Johnson LA, et al. AXL is a potential target for the treatment of intestinal fibrosis. Inflamm Bowel Dis;2020. DOI:https://doi.org/10.1093/ibd/izaa169
   Google Scholar
• Schwab R, Lim R, Goldberg R. Resolving intestinal fibrosis through regenerative medicine. Curr Opin Pharmacol. 2019;49:90–94.
   PubMed Web of Science ®Google Scholar
• Iswandana R, Pham BT, Suriguga S, et al. Murine precision-cut intestinal slices as a potential screening tool for antifibrotic drugs. Inflamm Bowel Dis. 2020;26(5):678–686.
   PubMed Web of Science ®Google Scholar
• Rodansky ES, Johnson LA, Huang S, et al. Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs. Exp Mol Pathol. 2015;98(3):346–351.
   PubMed Web of Science ®Google Scholar